We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

BioTek

BioTek Instruments, Inc., designs, manufactures, and distributes life science instrumentation. Its product line inclu... read more Featured Products: More products

Download Mobile App




Higher Female TSH Associated With Lower Mannan-Binding Lectin

By LabMedica International staff writers
Posted on 15 Jan 2020
Print article
Image: Synergy H1 Hybrid Multi-Mode Reader is a configurable microplate reader (Photo courtesy of BioTek)
Image: Synergy H1 Hybrid Multi-Mode Reader is a configurable microplate reader (Photo courtesy of BioTek)
Mannan-binding lectin (MBL) is a main component of the lectin pathway of the complement system. Lower MBL levels are associated with, among other conditions, hypothyroidism and adverse pregnancy outcomes.

In turn, adverse pregnancy outcomes and infertility may result from hypothyroidism, even in patients with high normal thyroid-stimulating hormone (TSH). An increased MBL blood level was found in hyperthyroid patients while decreased MBL levels were found in hypothyroid patients.

Endocrinologists at the Medical University of Lodz (Lodz, Poland) tested patients who were divided into two groups of 70 patients with low normal TSH (< 2.5 mIU/L) (Controls), and 25 patients (26.3% of the whole sample examined) with high normal TSH (≥2.5 mIU/L), which were well matched at baseline in terms of age and body mass index (BMI). Nineteen patients were previously diagnosed to be hypothyroid and therefore they were treated with L-thyroxine (25–150 μg daily).

The team measured in serum hormones (TSH, FT4, FT3), thyroid antibodies (i.e. thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TSHRAb)), among other laboratory parameters (such as total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), HDLC/cholesterol ratio, triglycerides (TGs), glucose, C-reactive protein (CRP), iron, and lipid peroxidation. Serum concentration of MBL was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercial human MBL ELISA kit (RayBiotech, Inc, Peachtree Corners, GA, USA), with a detection threshold of 0.03 ng/mL. The readings were performed on a Synergy H1 microplate reader (BioTek, Winooski, VT, USA) with a wavelength of 450 nm.

The investigators found that serum MBL level was lower in women with TSH ≥ 2.5 mIU/L than with TSH < 2.5 mIU/L. This association was confirmed by univariate regression analysis. MBL level was significantly lower in patients with abnormally low HDLC/cholesterol ratio and a positive correlation was found between MBL level and HDL/cholesterol ratio. MBL level was not statistically associated with L-thyroxine treatment when evaluated by the univariate logistic regression analysis. MBL level did not correlate with either TPOAb or TgAb.

The authors concluded that in women of reproductive age with normal thyroid tests, lower MBL is associated with high normal TSH and with less favorable lipid profile. Therefore, treatment with L-thyroxine should be considered in women of reproductive age with TSH ≥ 2.5 mIU/l. The study was published on January 3, 2020 in the journal BMC Endocrine Disorders.

Related Links:
Medical University of Lodz
RayBiotech Inc
BioTek


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.